HIMS Core Business Faces Challenges in Guidance, GLP-1 Prices & NVO
•March 1, 2026
0
Why It Matters
The shift away from GLP‑1 revenue and exposure to litigation could redefine Hims & Hers’ growth trajectory, influencing investor sentiment across the telehealth and personalized‑medicine sectors.
Key Takeaways
- •Hims & Hers missed Q1 revenue guidance, prompting share dip.
- •Core sexual health and dermatology grew over 30% YoY.
- •GLP‑1 pricing decline and regulatory crackdown hurt profitability outlook.
- •Legal exposure from Novo Nordisk lawsuit caps near‑term valuation.
- •Management pivots to holistic personalized medicine beyond GLP‑1 products.
Summary
Hims & Hers reported Q4 results after the bell, with mixed performance, drawing investor focus on its GLP‑1 program and forward guidance.
The company posted EPS of $0.08, double expectations, but revenue of $617 million fell short of the $619 million forecast. For Q1, guidance of $600‑$625 million disappointed analysts who had modeled $654 million, reflecting pressure from GLP‑1 price erosion and regulatory scrutiny.
Analysts Christine Short highlighted a 30%+ growth in the core sexual‑health and dermatology segments, noting that only a small fraction of the 2.5 million subscribers use GLP‑1. Brian Tanquilut reiterated a “hold” rating, citing the Novo Nordisk patent lawsuit and the fading GLP‑1 halo as near‑term valuation caps, while emphasizing the company’s shift toward a holistic, personalized‑medicine model.
The market’s initial sell‑off has softened as investors reassess the pivot away from GLP‑1 dependence. However, ongoing legal liabilities and uncertain GLP‑1 pricing dynamics keep the stock’s upside limited, making execution of the broader telehealth strategy critical for long‑term growth.
Original Description
Forward-looking guidance initially plagued Hims & Hers (HIMS) shares, says Christine Short, though she believes leadership did a good job at "refocusing" goals. She points to the company's businesses beyond GLP-1s showing signs of promise. Brian Tanquilut notes headwinds still hitting the firm, including a lawsuit from Novo Nordisk (NVO). Prices of GLP-1 drugs coming down only adds to his bearish thesis.
Segment originally aired Tuesday, February 24, 2026.
======== Schwab Network ========
Empowering every investor and trader, every market day.
Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe
Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185
Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7
Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore
Watch on DistroTV - https://www.distro.tv/live/schwab-network/
Follow us on X – https://twitter.com/schwabnetwork
Follow us on Facebook – https://www.facebook.com/schwabnetwork
Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/
About Schwab Network - https://schwabnetwork.com/about
#hims #hers #glp1 #weightloss #drugs #drug #pipeline #medicine #online #healthcare #novo #novonordisk #investing #trading #schwabnetwork
0
Comments
Want to join the conversation?
Loading comments...